ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Relay Therapeutics Inc

Relay Therapeutics Inc (RLAY)

13,52
-1,02
(-7,02%)
Geschlossen 06 Juni 10:00PM
13,01
-0,51
( -3,77% )
Vor Marktöffnung: 10:22AM

Relay Therapeutics Inc (RLAY) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
13,01
( -3,77% )
Gebot
12,93
Fragen
14,05
Volumen
510
0,00 Tagesbereich 0,00
2,98 52-Wochen-Bereich 17,47
Marktkapitalisierung
Handelsende
13,52
Handelsbeginn
-
Letzte Trade
10
@
13.54
Letzter Handelszeitpunkt
10:22:50
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 3.672.808
Ausgegebene Aktien
217.940.332
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-9,78
Gewinn pro Aktie (EPS)
-1,57
Erlöse (LTM)
10,68M
Nettogewinn (LTM)
-272,71M

Über Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a p... Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Cambridge, United States
Gegründet
2026
Relay Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker RLAY. The last closing price for Relay Therapeutics was US$13,52. Over the last year, Relay Therapeutics shares have traded in a share price range of US$ 2,98 to US$ 17,47.

Relay Therapeutics currently has 217.940.332 shares in issue. The market capitalisation of Relay Therapeutics is US$2,84 billion. Relay Therapeutics has a price to earnings ratio (PE ratio) of -9.78.

RLAY Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-1-7.1377587437514.0117.4712.925586567014.85801001CS
40.211.64062512.817.4711.62521162213.57506005CS
122.5924.856046065310.4217.479.265376072213.35235699CS
265.1765.9438775517.8417.477.09302302411.41963382CS
529.57278.1976744193.4417.472.9824682138.85767982CS
1561.4112.155172413811.617.471.77518983837.49834525CS
260-22.09-62.934472934535.138.6051.775153856911.16250228CS

RLAY - Frequently Asked Questions (FAQ)

What is the current Relay Therapeutics Inc share price?
The current share price of Relay Therapeutics Inc is US$ 13,01
How many Relay Therapeutics Inc shares are in issue?
Relay Therapeutics Inc has 217.940.332 shares in issue
What is the market cap of Relay Therapeutics Inc?
The market capitalisation of Relay Therapeutics Inc is USD 2,84B
What is the 1 year trading range for Relay Therapeutics Inc share price?
Relay Therapeutics Inc has traded in the range of US$ 2,98 to US$ 17,47 during the past year
What is the PE ratio of Relay Therapeutics Inc?
The price to earnings ratio of Relay Therapeutics Inc is -9,78
What is the cash to sales ratio of Relay Therapeutics Inc?
The cash to sales ratio of Relay Therapeutics Inc is 312,33
What is the registered address of Relay Therapeutics Inc?
The registered address for Relay Therapeutics Inc is 60 Hampshire Street, Cambridge, Massachusetts, 02139
What is the Relay Therapeutics Inc website address?
The website address for Relay Therapeutics Inc is www.relaytx.com
Which industry sector does Relay Therapeutics Inc operate in?
Relay Therapeutics Inc operates in the Biotechnology & Life Sciences sector

RLAY Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen